English हिन्दी
Connect with us

Latest Science News

AI-Integrated retinal-imaging device from India shows promising results in screening for Diabetic Retinopathy

Published

on

AI-Integrated retinal-imaging device from India shows promising results in screening for Diabetic Retinopathy

ANI | Updated: Sep 12, 2019 14:02 IST

Bengaluru (Karnataka) [India] Sept 12(ANI/BusinessWire India): Diabetic Retinopathy (DR), is asymptomatic and affects nearly 20per cent of the 70 million diabetic patients in India.

Timely and accessible DR screening can enable early detection, preventing needless blindness. Nearly 70per cent of the population, especially those in rural areas lack access to specialists, given the very low specialist to population ratio of 1:100000 in some areas. A landmark study published in the August issue of JAMA Ophthalmology (Journal of the American Medical Association), reports the feasibility of using a smartphone-based retinal camera with the world’s first, in-built automated, offline Artificial Intelligence (AI) algorithm, the MEDIOS-AI, designed by Bangalore-based Remidio Innovative Solutions, to implement sensitive and scalable screening models for DR.

A team from Aditya Jyot Foundation for Twinkling Little Eyes, Mumbai, led by Dr Natarajan, President of the All India Ophthalmology Society, has till date screened more than 1300 patients with diabetes mellitus in civic dispensaries in Mumbai for DR and validated the diagnostic accuracy of MEDIOS-AI to detect Referable DR, a condition requiring immediate specialist consult. The AI instantly provides a report in less than 10 seconds, on the smartphone.

Florian Savoy (VP, Data Sciences and AI) and Bhargav Sosale (VP, Software Design), the architects of Remidio’s smartphone-based AI solution, suggest that the novel, offline AI platform is ‘extendable to Glaucoma, AMD and other sight-threatening chronic diseases’.

The images were captured on Remidio’s smartphone-based, non-mydriatic, portable camera, the NM-FOP 10 and subjected to automated analysis by MEDIOS-AI, with simultaneous grading by vitreoretinal specialists. MEDIOS-AI relied on 2 convolutional neural networks, based on the MobileNet architecture – one assessing the image quality, and the other separating healthy images from images with referable DR (RDR). The clinical sensitivity and specificity of the MEDIOS-AI algorithm were found to be 100per cent and 88.4per cent for RDR, 85.2per cent and 92.0per cent for any DR respectively, exceeding US FDA’s superiority endpoints of an RDR sensitivity of 85per cent and specificity of 82.5per cent.

Dr TY Alvin Liu, MD, Assistant Professor of Ophthalmology at Johns Hopkins Bloomberg School of Public Health, in an invited commentary, calls the study ‘paradigm-shifting’.

“The study paves the way in implementing large scale models for screening for DR, even in locations with no internet infrastructure. This is a step ahead of the approach taken by Google and other AI companies that need their AI models to run on external servers, necessitating internet access,” said Dr Natarajan, MD.

“Technologies like Remidio NMFOP and Medios Offline AI, are necessary to move screening closer to the nearly 400 million patients at risk of blindness globally, due to chronic, asymptomatic conditions like Diabetic Retinopathy,” said Dr Anand Sivaraman, CEO, Remidio.

This story is provided by Businesswire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

Latest Science News

ISRO-European Space Agency sign agreement for advancing human spaceflight

Dr. Aschbacher expressed gratitude to Dr. Somanath for his address at the ESA Council, noting that the agreement lays a solid foundation for ongoing cooperation between the two agencies.

Published

on

ISRO on Saturday announced that it has signed an agreement with the European Space Agency (ESA) to collaborate on astronaut training, mission execution, and research initiatives. The agreement was formalised by ISRO Chairman Dr. S Somanath and ESA Director General Dr. Josef Aschbacher.

This partnership establishes a framework for cooperative efforts in human space exploration and research, focusing on areas such as astronaut training, experiment development and integration using ESA facilities on the International Space Station (ISS), human and biomedical research experiments, and joint educational outreach programs, according to ISRO’s statement.

For the upcoming Axiom-4 mission, where ISRO’s Gaganyatri will be part of the crew alongside an ESA astronaut, both organizations will work together to conduct experiments proposed by Indian Principal Investigators on the ISS.

Moreover, the collaboration aims to include participation in ESA’s human physiological studies, technology demonstration experiments, and further joint educational outreach initiatives.

During the announcement, Dr. Somanath emphasised that ISRO has developed a roadmap for human spaceflight activities, and with the approval of the Bharatiya Antariksh Station (BAS), India’s planned indigenous space station, there is an opportunity to foster interoperability between human spaceflight programs.

Dr. Aschbacher expressed gratitude to Dr. Somanath for his address at the ESA Council, noting that the agreement lays a solid foundation for ongoing cooperation between the two agencies.

The leadership of both ISRO and ESA conveyed their satisfaction with the progress of the joint projects related to the Axiom-4 mission and emphasized the importance of continuing collaborative efforts in human spaceflight in the future, according to ISRO’s statement.

ISRO has stated that the newly signed agreement creates a framework for collaboration in human space exploration and research. This partnership emphasizes astronaut training, support for experiment development and integration—which includes utilising ESA facilities on the International Space Station—along with conducting human and biomedical research experiments and engaging in joint educational and outreach initiatives.

In preparation for the upcoming Axiom-4 mission, which will feature ISRO’s Gaganyatri alongside an ESA astronaut, both agencies are working together to implement experiments proposed by Indian Principal Investigators on the ISS. Additionally, ISRO is actively pursuing participation in ESA’s human physiological studies, technology demonstration experiments, and joint educational outreach efforts.

Continue Reading

India News

ISRO-NASA mission: Astronaut Shubhanshu Shukla to be 2nd Indian to travel to space, 40 years after Rakesh Sharma

Nair serves as the contingency astronaut, ready to step in should Shukla be unable to proceed.

Published

on

Group Captain Subhanshu Shukla is poised to become the first Indian in four decades to journey into space, with the Indian Space Research Organisation (ISRO) designating him as the ‘primary’ astronaut for the inaugural ISRO-NASA mission to the International Space Station, anticipated to commence after October this year.

On Friday, ISRO announced the selection of Shukla, 39, and Group Captain Prasanth Balakrishnan Nair, 48, for the Axiom-4 mission, appointing Shukla as the ‘prime’ astronaut, implying his primary role in traveling to the ISS. Nair serves as the contingency astronaut, ready to step in should Shukla be unable to proceed.

To date, Rakesh Sharma remains the sole Indian to have ventured into space, having done so in 1984 as a wing commander aboard a Soviet spacecraft. Shukla and Nair are among four Indian Air Force officers chosen for India’s pioneering manned space mission, Gaganyaan, slated for a tentative launch next year.

According to an ISRO official, the duo will engage in eight weeks of mission-specific training. The Axiom-4 mission, orchestrated by private space enterprise Axiom Space in collaboration with NASA, will be propelled by a SpaceX rocket. Joining Shukla will be three astronauts from Poland, Hungary, and the United States. This mission is the result of an accord between New Delhi and Washington during Prime Minister Narendra Modi’s U.S. visit last year.

The Axiom-4 spacecraft will remain affixed to the ISS for a duration of 14 days, ferrying not just astronauts but also cargo and supplies to the station. A launch date has not been pinpointed. According to NASA’s website, the mission is planned for no earlier than October 2024, but Poland’s space agency recently suggested the mission could slip into next year. Shukla is a fighter pilot from Lucknow in Uttar Pradesh and was commissioned into the IAF in 2006.

He has spent more than 2,000 hours on many IAF fighter jets, including Sukhoi-30 MKIs, MiG-21s, MiG-29s, Jaguars, Hawks, Dorniers, and the AN-32 aircraft. Nair, who won the Sword of Honour at the Air Force Academy, was commissioned into the IAF in 1998. A category ‘A’ flying instructor and test pilot, having flown over 3,000 hours, he is an alumnus of the United States Staff College and has commanded a Sukhoi-30 squadron.

The Gaganyaan mission of India draws on the experience and expertise gained from the Indian astronauts’ experiences with the ISS mission. “This is a collaborative effort between the two countries with the United States, and it benefits both,” said Somanath, chairman of ISRO, in 2023. “Training in the US and the subsequent discussions will enhance a lot in designing our Gaganyaan mission.”

Continue Reading

India News

President Droupadi Murmu launches India’s first homegrown CAR T-cell therapy for cancer treatment

The gene-based therapy, which is developed by the IIT Bombay and Tata Memorial Centre, is being rolled out in India at about one-tenth of its price outside the country.

Published

on

By

President Droupadi Murmu on Thursday launched India’s first indigenously-developed CAR T-cell therapy, a gene-based therapy, for cancer treatment, hailing it as a breakthrough that provides new hope for humankind in the battle against the diseases.

Speaking at the launch event at the Indian Institute of Technology (IIT) Bombay, Murmu said the indigenous development of the CAR T-cell therapy was an example of the Make in India initiative.  

The gene-based therapy, which is developed by the IIT Bombay and Tata Memorial Centre, is being rolled out in India at about one-tenth of its price outside the country, as per the senior official.

In CAR T-cell therapy, a patient’s T-cells, which is a type of immune system cell or stem cell, are modified in the laboratory and inserted back into the patient to attack and destroy cancer cells after editing the stem cell.

The NexCAR19 CAR T-cell therapy, the country’s first Made in India CAR T-cell therapy, is expected to bring down the cost of treatment significantly.

During her speech, Murmu said that this therapy is considered a phenomenal advance in medical sciences. The development of this therapy is also an example of the Make in India initiative and speaks volumes about Indian scientists and physicians, she added.

The launch of India’s first gene therapy is a significant breakthrough in the battle against cancer. As this line of treatment, named CAR T-cell therapy, is accessible and affordable, it provides a new hope for the whole of humankind, President Murmu further added.

The Tata Memorial Centre director Sudeep Gupta said the CAR T-cell therapy was enormously expensive and out of the reach of an overwhelming majority of people.

Asserting that, he said NexCar19 needs to be custom manufactured for every patient under the most stringent conditions, but it has been rolled out at approximately one-tenth of the price at which it is available outside India.

The treatment costs approximately Rs 4 crore abroad against Rs 30 lakh in India, said IIT Bombay director Prof Subhasis Chaudhuri.

He further said that the low-cost CAR T-cell therapy was a huge achievement for the country and cancer patients, and places India firmly on the global map of cell and gene therapy.

Comparing the achievement of Chandrayaan-3 with CAR T-cell therapy, Chaudhuri asserted that CAR-T cell therapy heralds India’s entry into the cell and genetic engineering group.

The Tata Memorial Centre director Gupta said the treatment will help some 20,000 Indians every year, and its rollout is a milestone in the field of cancer care and genetic engineering.

He added the CAR T-cell was not only a scientific achievement of the highest order but also had immense practical application. NexCAR19 will save many, many lives and wipe many, many tears, he emphasised.

Continue Reading

Trending

© Copyright 2022 APNLIVE.com